Peregrine Pharmaceuticals Doses First Patient In Phase II Clinical Trial Of Bavituximab In Patients With Advanced Breast Cancer
Feb 13th 2008Drug InformationBreast Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), announced that patient dosing has begun in its clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
